FIELD: biotechnology.
SUBSTANCE: invention relates to new conjugates of antibodies with drugs, and can be used in medicine.
EFFECT: invention discloses the possibility of using conjugates of trastuzumab with monomethylauristatin E (MMAE), in which the conjugated fragments are connected through various PEG linkers, in the manufacture of a drug for the treatment of HER-2 positive malignant neoplasms.
7 cl, 12 ex, 5 tbl, 18 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATE OF ANTIBODY AND DRUG, COMPOSITIONS BASED ON SAID CONJUGATE AND METHODS OF PRODUCING SAID CONJUGATE | 2015 |
|
RU2728235C2 |
| GLYCOSYLATED CONGUGATES OF MOLECULES WITH REPEATING MOTIF | 2010 |
|
RU2574201C2 |
| ANTIBODY-DRUG CONJUGATES WITH HIGH DRUG LOADING | 2015 |
|
RU2674979C2 |
| G-CSG CONJUGATES | 2001 |
|
RU2290411C2 |
| CONJUGATED IMMUNOGLOBULINS WITH C-TERMINAL LYSINE | 2016 |
|
RU2747581C2 |
| SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION BY MEANS OF GLYCOENGINEERING | 2014 |
|
RU2711935C2 |
| ANTIBODIES AND IMMUNOCONJUGATES AND THEIR APPLICATIONS | 2007 |
|
RU2639543C9 |
| COVALENT BONDED POLYPEPTIDE TOXIN AND ANTIBODY CONJUGATES | 2014 |
|
RU2682754C2 |
| COMPOSITIONS AND METHODS OF USING FOR TREATING METABOLIC DISORDERS | 2014 |
|
RU2704285C2 |
| MOLECULES SIMILAR TO FACTOR VII OR VIIA | 2001 |
|
RU2278123C2 |
